Latest News and Press Releases

ZyVersa's IC 100 blocked microglial NLRP1 inflammasome activation and reduced alpha-synuclein accumulation supporting its potential for Parkinson's Disease

Extracellular ASC has a crucial role in aggregation and deposition of amyloid A fibrils leading to associated chronic inflammatory conditions.

Inflammasome ASC Inhibitor IC 100 Reduced Inflammation and Restored Retinal Structure and Function in Retinopathy of Prematurity Animal Model

ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which is designed to inhibit formation of multiple types of inflammasomes, including NLRP3, and their associated ASC specks to attenuate...

Activation of multiple inflammasome pathways and extracellular ASC specks contribute to development and progression of common neurological diseases.

Activation of the inflammasome/ASC speck pathway has a vital role in synaptic degeneration in Alzheimer’s Disease (AD).

Brain inflammation from traumatic injury releases proinflammatory cytokines that activate inflammasomes in the heart leading to damaging inflammation.

White paper summarizes the research of leading inflammasome experts, Drs. Helen Bramlett, Juan Pablo de Rivero Vaccari, W. Dalton Dietrich, and Robert W. Keane, University of Miami Miller School of...

Juvenile idiopathic arthritis (“JIA”), a complex autoimmune inflammatory disorder, is the most common childhood chronic rheumatic diseaseThis is the first report documenting inflammasome activation in...

Prolonged systemic inflammation contributes to poor clinical outcomes in severe alcohol-associated hepatitis (“AH”) even after cessation of alcohol useReported data demonstrate a central role of NLRP3...